Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
The investigators would like to propose a phase-2 prospective multicenter trial evaluating
the efficacy of rituximab combination with our current chemotherapy strategy for adult Acute
Lymphoblastic Leukemia (ALL), in order to prove out whether the addition of rituximab during
induction, consolidation, and post-alloHCT status can improve the outcome in terms of
relapse-free survival (RFS) when compared with our prior data as a historical control.